Category: Oncotarget

Oncotarget News

Oncotarget | New Oncology-Focused Papers Published in Volume 13

June 23, 2022

BUFFALO, NY- June 23, 2022 – At the start of 2022, Oncotarget began publishing research papers in a continuous publishing format in yearly volumes. As of June 23, 2022, Oncotarget has... read more

PRESS RELEASE: Impact Journals is sponsoring Team Open Access on June 25, 2022, in the annual cycling event to end cancer: The Ride for Roswell.

Oncotarget

Impact Journals Sponsors 2022 Ride For Roswell

June 14, 2022

Impact Journals is sponsoring Team Open Access on June 25, 2022, in the annual cycling event to end cancer: The Ride for Roswell.BUFFALO, NY- June 14, 2022 – The&... read more

Oncotarget

Behind the Study: IGF-pathway Biomarkers and Lung Cancer

June 14, 2022

Dr. Alexander Pohlman from Rush Medical College, Rush University Medical Center, Chicago, IL, describes a recent review published by Oncotarget that he co-authored entitled, “The role of IGF-pathway biomarkers in... read more

Figure 3: Similar gene expression patterns between endocrine-resistant breast cancer and triple-negative breast cancer.

Oncotarget

Novel Group of Genes That Cause Endocrine Resistance in Breast Cancer Identified by Dynamic Gene Expression Analysis

June 8, 2022

Our findings identify 34 novel genes for further study as potential therapeutic targets for treatment of endocrine-resistant BC and TNBC.”BUFFALO, NY- June 8, 2022 – A research paper was recently... read more

Figure 1: Development of an NF-κB activity related RNA expression classifier.

Oncotarget

Oncotarget | NF-κB Over-Activation Portends Improved Outcomes in HPV+ HNSCC

May 25, 2022

Since clinicians are exploring therapeutic deintensification for HPV+ HNSCC, identifying patients with good or poor prognosis using the NF-κB Activity Classifier may be useful to guide therapeutic decisions.”BUFFALO,... read more

CancerOmicsNet: a multi-omics network-based approach to anti-cancer drug profiling

Oncotarget

Anti-Cancer Drug Profiling With CancerOmicsNet

May 19, 2022

BUFFALO, NY- May 19, 2022 – A new research paper was published in Volume 13 of Oncotarget, entitled, “CancerOmicsNet: a multi-omics network-based approach to anti-cancer drug profiling.”Researchers from Louisiana State... read more

Oncotarget

Impact Journals to Present Scientific Integrity Process at 2022 SSP Annual Meeting

May 16, 2022

Impact Journals is a supporter and exhibitor at the Society for Scholarly Publishing (SSP) 44th Annual meeting—taking place from June 1–3, 2022, at the Sheraton Grand Chicago Riverwalk... read more

Oncotarget

Testimonial: Dr. Mark Woodford

May 3, 2022

Dr. Mark Woodford, Assistant Professor at the Department of Urology, SUNY Upstate Medical University, Syracuse, NY, describes his experience publishing the meeting report, “Seventh BHD international symposium: recent scientific and... read more

Figure 2: TMB distribution in non-small cell lung cancer

Oncotarget

Mutational Burden in Lung Cancer Studied in Multisite Cohort

April 25, 2022

BUFFALO, NY-April 25, 2022 – A new research paper, entitled, “Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study,” was published in Oncotarget... read more

Dr. Stanley Lipkowitz and Dr. Yoshimi Endo Greer

Oncotarget

Behind the Study: How ONC201 Kills Breast Cancer Cells

April 22, 2022

Dr. Stanley Lipkowitz and Dr. Yoshimi Endo Greer from the Women’s Malignancies Branch at the National Cancer Institute discuss a research paper they co-authored that was published by Oncotarget... read more